Neoceptor concept based on molecular complementarity in GPCRs: A mutant adenosine A3 receptor with selectively enhanced affinity for amine-modified nucleosides

Journal of Medicinal Chemistry

Volumn 44, Issue 24, 2001, Pages 4125-4136

  Jacobson, K A ^a   Gao, Z G ^a   Chen, A ^a   Barak, D ^a,b   Kim, S A ^a   Lee, K ^a   Link, A ^c   Van Rompaey, P ^d   Van Calenbergh, S ^d   Liang, B T ^e  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH   (Israel)

^c UNIVERSITY OF HAMBURG   (Germany)

^d Lab voor Medicinale Chemie (FFW)   (Belgium)

^e HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 CHLOROADENOSINE; 4 [2 CHLORO 6 [(3 IODOPHENYLMETHYL)AMINO]PURIN 9 YL] 1 (METHYLAMINOCARBONYL)BICYCLO[3.1.0]HEXANE 2,3 DIOL; 9 CHLORO 2 (2 FURYL) 5,6 DIHYDRO 5 IMINO 1,2,4 TRIAZOLO[2,3 C]QUINAZOLINE; ADENOSINE 5' (N ETHYLCARBOXAMIDE); ADENOSINE RECEPTOR BLOCKING AGENT; ADENOSINE RECEPTOR STIMULATING AGENT; MRS 1898; N 6 (3 IODOBENZYL) 2 CHLOROADENOSINE 5' N METHYLURONAMIDE; NUCLEOSIDE; UNCLASSIFIED DRUG; VUF 8504;

ARTICLE; BINDING AFFINITY; DRUG MECHANISM; DRUG SYNTHESIS; HUMAN; MOLECULAR MODEL; MUTATION; RECEPTOR AFFINITY;

EID: 0035935737     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm010232o     Document Type: Article

References (57)

1. Therapeutic potential of adenosine kinase inhibitors
2. Effects of avitriptan, a new 5-HT 1B/1D receptor agonist, in experimental models predictive of antimigraine activity and coronary side-effect potential
3. 1-selective agonists
4. 3 receptor: Sustained cardioprotection
5. 3 receptor stimulation and cerebral ischemia
6. 2 receptors in rat brain tissue
7. Electrophysiologic effects of dipyridamole on atrioventricular nodal conduction and supraventricular tachycardia. Role of endogenous adenosine
8. Protective effects of adenosine in myocardial ischemia
9. Brain adenosine receptors as targets for therapeutic intervention in neurodegenerative diseases
10. Preconditioning with ischemia: A delay of lethal cell injury in ischemic myocardium
11. Ischemic preconditioning. Nature's own cardioprotective intervention
12. 3 receptors
13. 3 adenosine receptors: Novel ligands and paradoxical effects
14. 3 receptors
15. 3 adenosine receptors regulate Cl- channels of nonpigmented ciliary epithelial cells
16. 1-adenosine receptor: Studies on the ligand binding site by site directed mutagenesis
17. A threonine residue in the seventh transmembrane domain of the human A1 adenosine receptor mediates specific agonist binding
18. 1 adenosine receptors. Two amino acids are responsible for species differences in ligand recognition
19. 2a adenosine receptor
20. Identification of the adenine binding site of the human A1 adenosine receptor
21. Molecular architecture of G protein-coupled receptors
22. 2a adenosine receptors are required for ligand recognition
23. 13 in agonist recognition
24. 278 in ligand binding and sodium modulation
25. 3 adenosine receptors
26. 3 adenosine receptor
27. 3 adenosine receptors: Design of selective ligands and therapeutic prospects
28. Ring-constrained (N)methanocarba-nucleosides as adenosine receptor agonists: Independent 5′-uronamide and 2′-deoxy modifications
29. Aminonucleosides and their derivatives. IV. Synthesis of the 3′-amino-3′-deoxynucleoside 5′-phosphates
30. Nucleic acid related compounds. 71. Efficient general synthesis of purine (amino, azido, and triflate)-sugar nucleosides
31. 1 receptor antagonists
32. Diprotected triflylguanidines: A new class of guanidinylation reagents
33. Aminoglucosides and their derivates; IV. A new synthesis of 1,2,5-tri-O-acyl-3-azido-3-deoxy-β-D-ribofuranose
34. Nucleoside synthesis with trimethylsilyl triflate and perchlorate as catalysts
35. 6-phenylisopropyladenosine
36. 3 adenosine receptor activation triggers phosphorylation of protein kinase B and protects rat basophilic leukemia 2H3 mast cells from apoptosis
37. Adenosine kinase inhibitors as a novel approach to anticonvulsant therapy
38. 3-selective adenosine agonists
39. 3 receptor
40. 3 adenosine receptors by site-directed mutagenesis
41. Crystal structure of rhodopsin: A G protein-coupled receptor
42. Conversion of antagonist-binding site to metal-ion site in the tachykinin NK-1 receptor
43. 1 receptor
44. Controlling signaling with a specifically designed Gi-coupled receptor
45. Interaction of glutamine 165 in the fourth transmembrane segment of the human neurokinin-1 receptor with quinuclidine antagonists
46. Biologic bypass with the use of adenovirus-mediated gene transfer of the complementary deoxyribonucleic acid for vascular endothelial growth factor 121 improves myocardial perfusion and function in the ischemic porcine heart
47. Variability of human systemic humoral immune responses to adenovirus gene transfer vectors administered to different organs
48. High efficiency adenovirus-mediated gene transfer to cardiac myocytes after single-pass coronary delivery
49. Efficient and stable transduction of cardiomyocytes after intramyocardial injection or intracoronary perfusion with recombinant adeno-associated virus vectors
50. 2-adrenergic receptor in the heart: Prospects for molecular ventricular assistance
51. 3 adenosine receptor
52. 50) of an enzyme reaction
53. 1 receptor: Structure-activity relationships and receptor docking
54. 3 adenosine receptor antagonists: Structural homology and receptor docking
55. GPCRDB: An information system for G protein-coupled receptors
56. An all-atom force field for simulation of protein and nucleic acids